629: GLP-1 opportunities and blind spots for the food industry
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
629: GLP-1 opportunities and blind spots for the food industry
-
ナレーター：
-
著者：
GLP-1 medications are not a silver bullet. That's not a controversial statement, but it is one that tends to get lost in a media narrative that swings between miracle cure and moral panic.
The more interesting question for the food industry might be: what actually happens to people's diets when they're on these drugs, and what do they need from food, from support services, and from manufacturers, both during treatment and when they come off?
The honest answer, for now, is that the data is thin. People are eating less, but whether they're doing that through smaller portions, skipped meals, or a shift in macronutrient preference is largely uncharted territory.
In this episode of the Food Matters Live podcast, recorded at our London Olympia event, three specialists bring different lenses to the GLP-1 debate.
They cover dietary deficiencies, dietary support alongside the drugs, and how consumers’ tastes are changing as a result of taking GLP-1 medication.
If this has whet your appetite for next year’s Food Matters Live events - you can already register your interest to partner with us in London and Rotterdam. Just head to foodmatterslive.com